Core Insights - Medtronic has entered into a definitive agreement to acquire Scientia Vascular for $550 million, enhancing its neurovascular portfolio with innovative access technologies [1][1][1] - The acquisition aims to improve procedural efficiency in neurovascular care, addressing challenges in stroke treatment where timely intervention is critical [1][1][1] Company Overview - Scientia Vascular, based in Salt Lake City, Utah, employs approximately 310 people and specializes in access products for complex neurovascular conditions [1][1] - Medtronic's Neurovascular business is part of its broader Neuroscience Portfolio, focusing on eliminating the burden of stroke and other neurovascular diseases globally [1][1] Product Integration - Scientia's guidewires and catheters will be integrated with Medtronic's existing neurovascular products, enhancing the procedural workflow for physicians [1][1] - The acquisition is expected to provide a comprehensive portfolio that supports both hemorrhagic and acute ischemic stroke procedures [1][1] Market Impact - Stroke is the third leading cause of death and the leading cause of disability worldwide, with 12 million people affected annually [1][1] - The acquisition is anticipated to be minimally dilutive to Medtronic's adjusted EPS in FY27 and accretive thereafter, indicating a positive financial outlook post-acquisition [1][1]

Core Viewpoint - Medtronic plc will announce its financial results for the third quarter of fiscal year 2026 on February 17, 2026, following the end of the quarter on January 23, 2026 [1] Group 1: Financial Reporting - A video webcast discussing the financial results will begin at 7:00 a.m. CST on the announcement day [1] - A news release containing summary financial information will be issued at approximately 5:45 a.m. CST [1] - A replay and transcript of the prepared remarks will be available within 24 hours of the webcast [1] Group 2: Company Overview - Medtronic is headquartered in Galway, Ireland, and is a leading global healthcare technology company [1] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies and therapies [1] - Medtronic's mission is to alleviate pain, restore health, and extend life, focusing on innovative solutions in various medical fields [1]

Core Points - Medtronic plc announced the closing of a public offering of €750 million principal amount of 2.950% senior notes due 2030 and €750 million principal amount of 4.200% senior notes due 2045, totaling €1.5 billion [1][2] - The net proceeds from the offering are approximately €1.49 billion after deducting underwriting discounts and estimated expenses, which will be used to repay existing senior notes due 2025 [2] Company Overview - Medtronic plc, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing challenging health problems through innovative solutions [4] - The company employs over 95,000 people across more than 150 countries and offers technologies and therapies for 70 health conditions, including cardiac devices and surgical robotics [4]